Tiziana Life Sciences Ltd (TLSA) - Total Assets
Based on the latest financial reports, Tiziana Life Sciences Ltd (TLSA) holds total assets worth $11.49 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Tiziana Life Sciences Ltd - Total Assets Trend (1998–2025)
This chart illustrates how Tiziana Life Sciences Ltd's total assets have evolved over time, based on quarterly financial data. Also see market cap of Tiziana Life Sciences Ltd for the company's overall valuation and market capitalisation.
Tiziana Life Sciences Ltd - Asset Composition Analysis
Current Asset Composition (December 2025)
Tiziana Life Sciences Ltd's total assets of $11.49 Million consist of 74.4% current assets and 25.6% non-current assets. Review debt load of Tiziana Life Sciences Ltd to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 34.9% |
| Accounts Receivable | $4.26 Million | 37.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (1998–2025)
This chart illustrates how Tiziana Life Sciences Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See TLSA stock price and chart for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Tiziana Life Sciences Ltd's current assets represent 74.4% of total assets in 2025, an increase from 28.2% in 1998.
- Cash Position: Cash and equivalents constituted 34.9% of total assets in 2025, up from 21.1% in 1998.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 71.0% in 1998.
- Asset Diversification: The largest asset category is accounts receivable at 37.0% of total assets.
Tiziana Life Sciences Ltd Competitors by Total Assets
Key competitors of Tiziana Life Sciences Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Abivax SA
PA:ABVX
|
France | €547.14 Million |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.46 Billion |
|
Braveheart Bio, Inc. Common Stock
NASDAQ:BRVE
|
USA | $126.96 Million |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Lifecome Biochemistry Co Ltd
SHE:002868
|
China | CN¥729.16 Million |
|
Pulike Biological Engineering
SHG:603566
|
China | CN¥3.09 Billion |
|
Rocket Pharmaceuticals Inc
NASDAQ:RCKT
|
USA | $423.10 Million |
|
NEWRON PHARMACEUT. EO-20
XETRA:NP5
|
Germany | €40.03 Million |
Tiziana Life Sciences Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.76 | 1.02 | 8.79 |
| Quick Ratio | 0.76 | 1.02 | 8.72 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-2.66 Million | $160.00K | $62.09 Million |
Tiziana Life Sciences Ltd - Advanced Valuation Insights
This section examines the relationship between Tiziana Life Sciences Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 19.23 |
| Latest Market Cap to Assets Ratio | 9.96 |
| Asset Growth Rate (YoY) | 1.9% |
| Total Assets | $11.49 Million |
| Market Capitalization | $114.53 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Tiziana Life Sciences Ltd's assets at a significant premium (9.96x), suggesting investors see substantial growth potential or unique competitive advantages.
Positive Asset Growth: Tiziana Life Sciences Ltd's assets grew by 1.9% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Tiziana Life Sciences Ltd (1998–2025)
The table below shows the annual total assets of Tiziana Life Sciences Ltd from 1998 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $11.49 Million | +1.87% |
| 2024-12-31 | $11.28 Million | -7.39% |
| 2023-12-31 | $12.18 Million | -53.98% |
| 2022-12-31 | $26.48 Million | -45.77% |
| 2021-12-31 | $48.83 Million | -30.90% |
| 2020-12-31 | $70.66 Million | +3807.96% |
| 2019-12-31 | $1.81 Million | -66.85% |
| 2018-12-31 | $5.45 Million | +197.84% |
| 2017-12-31 | $1.83 Million | -63.75% |
| 2016-12-31 | $5.05 Million | -45.39% |
| 2015-12-31 | $9.25 Million | +276.02% |
| 2014-12-31 | $2.46 Million | +1852.38% |
| 2013-12-31 | $126.00K | +31.25% |
| 2012-12-31 | $96.00K | -84.64% |
| 2011-12-31 | $625.00K | -38.73% |
| 2010-12-31 | $1.02 Million | -41.04% |
| 2009-12-31 | $1.73 Million | -12.67% |
| 2008-12-31 | $1.98 Million | -31.74% |
| 2007-12-31 | $2.90 Million | -8.16% |
| 2006-12-31 | $3.16 Million | -8.22% |
| 2005-12-31 | $3.44 Million | -16.92% |
| 2004-12-31 | $4.14 Million | +25.23% |
| 2003-12-31 | $3.31 Million | +29.06% |
| 2002-12-31 | $2.56 Million | -22.89% |
| 2001-12-31 | $3.33 Million | -26.11% |
| 2000-12-31 | $4.50 Million | +91.49% |
| 1999-12-31 | $2.35 Million | -12.05% |
| 1998-12-31 | $2.67 Million | -- |
About Tiziana Life Sciences Ltd
Tiziana Life Sciences Ltd, a biotechnology company, engages in the development of transformative therapies for neurodegenerative and lung diseases in the United States. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for use in the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes… Read more